A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus
Novartis Pharmaceuticals · NCT07775924
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–99 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 2
- Target enrollment
- 259
- US sites recruiting
- 15
- Study start
- September 29, 2026
- Record last updated
- October 13, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study will evaluate the safety and efficacy of GIA632 in participants with moderate to severe cutaneous lichen planus (cLP).
Being studied: Placebo; GIA632
Conditions: Cutaneous Lichen Planus
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Key Inclusion Criteria
- Male or female (as assigned at birth) participants ≥ 18 years of age at the time of screening.
- Individuals with a diagnosis of cLP, confirmed
- histologically by a skin biopsy (either historically within 1 year prior to screening or at screening if historical one not available), and
- by physical examination by the investigator at screening.
- Moderate to severe cLP
- Two or more body regions affected (any two or more of the following: head and neck, trunk, upper extremities including hands, lower extremities including feet).
- Diagnosis of cLP inadequately controlled by at least one topical treatment for at least 3 months (either via continuous use or burst and taper regimen), or such treatment being considered not advisable, as per investigator judgement, assessed at screening.
Topical treatment includes, but is not limited to, topical corticosteroids, topical calcineurin inhibitors, topical cholecalciferol analogues, topical PDE4 inhibitors, topical JAK inhibitors, and topical aryl hydrocarbon receptor agonists.
Key Exclusion Criteria
- Individuals unable or unwilling to follow the study procedures, handle the electronic diary (eDiary), and/or to complete the study-related questionnaires.
- Diagnosis of drug-induced lichen planus (lichenoid drug eruption) or lichen planus pigmentosus.
- Presence of skin conditions that may interfere with study assessments, including histologic findings in the biopsy, as assessed at screening and baseline.
- Previous exposure to biologic drugs directly targeting IL-15 or any subunit of the IL-15 receptor.
- Use of prohibited medication and treatments.
Other protocol-defined inclusion/exclusion criteria may apply.
Recruiting US locations
Cahaba Derm and skin hlth ctr 27
Birmingham, AL 35244
Site contact: Wes Booth · +1 205 778 1564 · wbooth@cahabaderm.com
First OC Dermatology
Fountain Valley, CA 92708
Site contact: Keiry Espinoza · +1 714 531 2966 · kespinoza@dermcaremgt.com
Miami Derm and Laser Institute
Miami, FL 33173
Site contact: Swanee Cepero · +1 305 279 6060 · swaneec@miamidermlaser.com
Global Clinical Professionals
St. Petersburg, FL 33714
Site contact: Nailis Echevarria · +1 727 520 1427 · nechevarria@researchgcp.com
Skin Care Physicians Of Georgia
Macon, GA 31217
Site contact: Jennifer Smith · jlee@scpog.com
Dawes Fretzin Clinical Rea Group
Indianapolis, IN 46256
Site contact: Megan Kirchner · +1 317 516 5030#102 · mkirchner@ecommunity.com
Essential Medical Research
Overland Park, KS 66213
Site contact: Reena Nagavelli · 19186451992 · ReenaN@emedr.com
Louisiana Dermatology Associates
Baton Rouge, LA 70809
Site contact: Hilary Kingsley · +1 225 927 5663 · hkingsley@delricht.com
Delricht Research
New Orleans, LA 70115
Site contact: Emily Krambeck · +1 504 336 2667 · ekrambeck@delricht.com
Uni Of Michigan Health System
Ann Arbor, MI 48109
Site contact: Hyein Kim · +1 734 936 5504 · kihyein@med.umich.edu
Hamzavi Dermatology
Fort Gratiot, MI 48059
Site contact: Brynn Bemis · +1 810 455 1600 · bbemis@hamzavi.com
Skin Specialists PC
Omaha, NE 68144
Site contact: Carrie Hill · +1 402 334 7546 · carrie@lovelyskin.com
NextGen Clinical Research and Innovation Inc-Network
Mansfield, TX 76063
Site contact: Lakkureddi Alagarsamy · LakkureddiA@NextGenClinical.Us
Austin Inst for Clinical Research
Pflugerville, TX 78660
Site contact: Dominique Talamantes · +1 512 279 2545 · d.talamantes@atxresearch.com
RFSA Dermatology
San Antonio, TX 78213
Site contact: Jonathan Joseph · jonathanj.rfsadermatology@gmail.com
Study contacts (from the official record)
- Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
- Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com